Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia (AML) - with high reliability. Researchers at the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn have now shown this in a proof-of-concept study. Their approach is based on the analysis of the gene activity of cells found in the blood. Used in practice, this approach could support conventional diagnostics and possibly accelerate the beginning of therapy. The research results have been published in the journal “iScience”.
Cluster member and speaker of the Cluster of Excellence Prof. Joachim Schultze led the study in Bonn.
Publication
Scalable prediction of acute myeloid leukemia using high-dimensional machine learning and blood transcriptomics; Stefanie Warnat-Herresthal, Konstantinos Perrakis et al., iScience (2019),
DOI: 10.1016/j.isci.2019.100780
